Premium
Malignant fibrous histiocytoma of the pancreas
Author(s) -
Bastian Daniel,
Ramaswamy Annette,
Barth Peter J.,
Gerdes Berthold,
Ernst Michael,
Bartsch Detlef
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19990601)85:11<2352::aid-cncr9>3.0.co;2-7
Subject(s) - pancreas , immunohistochemistry , pathology , sarcoma , medicine , tumor suppressor gene , gene , oncogene , pancreatic disease , stomach , cancer research , biology , cancer , genetics , carcinogenesis , cell cycle
BACKGROUND Malignant fibrous histiocytoma (MFH) is the most common type of soft tissue sarcoma in adults; it occurs frequently in the extremities, the trunk, or retroperitoneal tissues. MFH rarely is detected in digestive organs, such as the liver or stomach. METHODS The authors report a patient with MFH of the pancreas who was treated with surgery alone. The tumor was studied for genetic alterations in the p53, p16 ink4a , and DPC4 tumor suppressor genes as well as the K‐ ras oncogene by immunohistochemistry, single strand conformation variant (SSCV) analysis, and direct DNA sequencing. RESULTS The authors believe that this is the 13th report of primary pancreatic MFH in the world literature and the first genetic analysis of this rare tumor. The patient is alive with no evidence of recurrence 34 months after surgery. Immunohistochemistry revealed no abnormal accumulation of the p53 protein and normal nuclear p16 expression. Mutation analysis of the p53, p16, DPC4, and K‐ ras genes showed only a polymorphism at codon 72 of the p53 gene and no mutations in any of the genes. CONCLUSIONS Genotypically, MFH of the pancreas is clearly different from other malignant pancreatic tumors, which further supports the hypothesis that this tumor is a rare but distinct entity. Cancer 1999;85:2352–8. © 1999 American Cancer Society.